Shanghai Ennovabio

Ennovabio is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on the DNA Damage Response (DDR) pathway to treat various cancers, including ovarian and other solid tumors. Its lead candidate, Senaparib (IMP4297), is a potent PARP inhibitor that has completed Phase 3 trials and is under regulatory review in China. Ennovabio leverages its proprietary R&D platform to build a robust pipeline of targeted therapies, including Wee1 and ATR inhibitors. The company aims to provide effective and accessible precision medicines for patients globally through internal innovation and strategic partnerships, such as its collaboration with Junshi Biosciences.